Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin domain-containing protein 2 (UBTD2), also known as dendritic cell-derived ubiquitin-like protein (DC-UbP), is a ubiquitin superfamily member characterized by the presence of a ubiquitin-like (UbL) domain and a ubiquitin-binding domain (UBD). UBTD2 is primarily involved in the regulation of protein ubiquitination by acting as a molecular scaffold that binds and coordinates the activity of the ubiquitin-activating enzyme E1 (UbE1/UBA1) and the deubiquitinating enzyme USP5, thereby modulating the cellular ubiquitin pool and homeostasis of protein ubiquitination and deubiquitination. UBTD2 was first identified in dendritic cells and is broadly expressed in human tissues. Although it is not currently considered a direct therapeutic target and no specific drugs are known to interact with it, emerging evidence suggests that altered UBTD2 function could impact cellular processes such as protein degradation, gene regulation, and possibly tumorigenesis via fusion with other proteins. The precise biologic and disease relevance of UBTD2 remains under investigation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin domain-containing protein 2 (UBTD2).